drugset
drugset / Trial / NCT06860243

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

NCT06860243 ↗

Phase 1 Completed 16 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelBasic science

Summary

Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.

Timeline

Start
2025-05-13
Primary completion
2026-02-09
Completion
2026-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Opevesostat Small molecule — Oral
Background Fludrocortisone Other / unclassified — Oral
Background Prednisone Other / unclassified — Oral

Indications

No indication recorded.